Amicus Therapeutics (NASDAQ:FOLD) Lowered to “Hold” Rating by StockNews.com

Amicus Therapeutics (NASDAQ:FOLD) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, November 7th. Cantor Fitzgerald upped their target price on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Jefferies Financial Group assumed coverage on Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 target price for the company. JPMorgan Chase & Co. increased their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Finally, Morgan Stanley restated an “equal weight” rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.88.

Amicus Therapeutics Trading Down 0.1 %

NASDAQ FOLD opened at $9.89 on Wednesday. The stock has a market cap of $2.96 billion, a P/E ratio of -29.09 and a beta of 0.60. Amicus Therapeutics has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The stock has a 50 day simple moving average of $10.51 and a two-hundred day simple moving average of $10.62. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders sold 30,401 shares of company stock valued at $339,363. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Xponance Inc. lifted its holdings in Amicus Therapeutics by 5.3% during the second quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 936 shares in the last quarter. Hazlett Burt & Watson Inc. lifted its stake in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares in the last quarter. Arizona State Retirement System lifted its stake in shares of Amicus Therapeutics by 2.6% during the 2nd quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock valued at $615,000 after buying an additional 1,577 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Amicus Therapeutics by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 1,884 shares during the period. Finally, OLD Second National Bank of Aurora purchased a new stake in Amicus Therapeutics in the 3rd quarter worth $26,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.